Prellis Biologics Raises $35M in Series C Funding
Prellis organic productsa San Francisco, Calif.-based biotherapy company raised $35 million in Series C funding.
The round, which brings funding to date to $64.5 million, was led by Celesta Capital and Avidity Partners with participation from Khosla Ventures, SOSV, True Ventures and Lucas Venture Group.
The company intends to use the funds to expand its proprietary human immune system-based drug discovery and development platform, EXIS™ (Externalized Human Immune System).
Led by CEO Michael Nohaile, Prellis Biologics, Inc. uses its proprietary high-resolution bioprinting technology to recreate and engineer human tissue in vitro. Prellis Externalized Immune System’s proprietary platform, EXIS™, accurately replicates the human immune response through the creation of lymph node organoids (LNO). With EXIS, Prellis is able to harness fully human immune responses for a variety of applications, including antibody discovery, immunogenicity assessment, and tumor immunity models.
Dr. Nohaile joins from Generate Biomedicines and succeeds Prellis Bio founder Dr. Melanie Matheu, who will assume the role of Chief Technology Officer and retain a seat on the Board of Directors. The company will also add two new members to the board: Lei Meng, principal therapeutic analyst at Avidity Partners, and Nobel Prize winner James Rothman, PhD, Sterling Professor of Cell Biology at Yale University.
Earlier this year, Prellis Bio announced collaboration and license option agreements with Sanofi and Bristol Myers Squibb.